HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Oncolytics Biotech (NASDAQ:ONCY) and maintained a $15 price target.
June 29, 2023 | 3:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncolytics Biotech's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $15 price target.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, the 'Buy' rating and $15 price target from HC Wainwright & Co. suggest a positive outlook for Oncolytics Biotech, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100